Lilly Grant Funding Disclosure May 27, 2008

Reactions to Publications Grant Funding Publishing Methodology Eli Lilly Philosophy Reactions to Publications Grant Funding Publishing Methodology How to Publish Pre and Post Publication Thoughts 2

What to publish in the future? Public Scrutiny and Press Best Interests of Industry Why publish? What to publish (CME, Charitable, Sponsorship, Clinical Trials, Patient Advocacy)? What to publish in the future? Public Scrutiny and Press Senate Finance Committee Inquiries Why publish?: Create transparency to public Highlight the good programs that Lilly and Pharma support At the time we had two Senate Finance Committee inquiries regarding grant funding and the subject of grant giving by pharma being used for off-label drug promotion was often in the press. Also states were expanding creating broad legislation regarding spending and gifts from Pharma companies to physicians, some of which included the benefit received by physicians for CME programs. Discuss that Lilly was the first to launch a clinical trial registry back in 2005(?) to create greater transparency of their clinical studies and to the quality of those studies. Aggregate Spend and State Law Reporting

Physician Participants Non-Physician Participants Promote Good Work of Pharma Physician Education Other Healthcare Practitioner Education Charitable Contributions ACCME Programs Hours of Instruction Physician Participants Non-Physician Participants Grand Total 93,582 712,163 8,255,017 4,577,078 Hit bullets and then cite ACCME 2006 Annual report statistics regarding number of programs and HCP’s educated Source: ACCME 2006 Annual Report 4 4

Government Press Industry Advocacy Groups Internal Praise from Senator Grassley and Capitol Hill for initiative Consulted on other initiatives (gained added credibility) N/A Clarification what is disclosed Enough disclosure Other data to be disclosed Other Pharma company plans Lilly has no additional plans Positive articles in WSJ, trade press, et. al. N/A Why did Lilly decide to disclose What is the purpose Create Transparency Highlight the good programs Lilly supports Generally positive Companies looking to undertake similar initiatives Moved transparency dialogue to forefront N/A Did Lilly do too much too fast Did Lilly drive the Sunshine Act and other regulations Right information to publish Thought this was the right information to disclose Pros Positive recognition Improve awareness of good programs Improved credibility Additional scrutiny Exposure for smaller groups strains resources N/A Senior management supportive Employees feel good about what company is doing N/A Want more information about programs Ongoing assessment of areas for disclosure and transparency Cons Questions Response 5

Potential Publishing Methodology Technical Challenges Data Repository Approving data for publication Consistency, accuracy of data Controls Separation of divisions (Sales, Marketing, etc.) Following processes and procedures Documentation SOPs LOA language Responses Disclosure Level of detail Responsible party Validity of data Format of disclosure Preparation & Training Whom to train Why train Continuous training Potential Publishing Methodology Discuss new training created and required for all US ee’s narrated by Dr. Alan Breier, VP Medical and Chief Medical Officer Need to ensure all US ee’s understand external regulations regarding grants since grants will be publicly disclosed and understand appropriate interactions with HCP’s and HC organizations regarding grants One US policy on grants and consistent SOP’s in the various areas within the company that give grants Disclosure report process and reviews that occur prior to posting (LGO, legal, Compliance, and Advocacy folks) to ensure information is accurate and has a clear grant description Discuss technical challenges- one grant application for all areas, one process, consistent SOP’s, coordination and communication across grant offices, etc

Publication Experience Positive reactions internally and externally. No challenges from funding recipients Contacting key organizations before publication was beneficial and helped industry perception No noticeable change in provider interaction with Lilly Preparation and training is key to successfully publishing grant information Discussion Items Is disclosing more or less grant detail information better? What has been the government’s reaction? Has the perception of the industry changed? Missing qualitative aspect of our funding. How good was it? How effective was it? Use surveys or other criteria to determine this. 7 7